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Abstract (143 words): 
Substantial obstacles exist to the design and conduct of treatment trials for carbapenem-resistant 
bacterial infections. These include the lack of a widely acceptable optimised standard of care, 
control regimen, with varying antimicrobial susceptibilities and clinical contraindications making 
specific intervention regimens infeasible, combined with diagnostic and recruitment challenges. To 
address these obstacles we propose extending the network meta-analysis approach to individual 
randomisation of patients. Specifically, of a “network” of X regimens of interest for life-threatening 
carbapenem-resistant infections, each patient would be randomised only to regimens considered 
clinically reasonable for that patient at that time, incorporating susceptibility, toxicity profile, 
pharmacokinetic/pharmacodynamics data, availability and physician judgement. We propose a novel 
trial design, building on network meta-analysis methods, to maximise the relevance to each 
individual patient, and to enable the top-ranked regimens from any personalised randomisation list 





Text (2945 words):  
 
Broad-spectrum antimicrobial resistance (AMR) and/or multi-drug resistance is impacting treatment 
decisions and patient outcomes from bacterial infections worldwide, particularly in Asia and 
southern Europe. Infections with carbapenem-resistant Enterobacteriaceae (CRE), Acinetobacter 
baumanii or Pseudomonas aeruginosa are the clearest threat, with multiple documented 
mechanisms of carbapenem resistance.1 Many of these mechanisms co-occur with resistance to 
multiple antibiotic classes and are carried on mobile genetic elements, including plasmids, which 
facilitate their spread. This leads to “mosaic” patterns of resistance, requiring personalisation of 
antibiotic therapy using antimicrobial susceptibility testing.  
 
Numerous areas of clinical uncertainty surround the treatment of these highly resistant infections, 
particularly because in vitro data (e.g. from hollow fibre models) suggests antibiotic combinations 
may be synergistic2 or antagonistic.3 The situation is made more complex by a lack of standardisation 
of in vitro pharmacokinetic/pharmacodynamic (PK/PD) models and dose optimisation methods for 
single antibiotic drug development programs,4 recently highlighted by National Institute of Allergy 
and Infectious Diseases workshops.5,6 There is further lack of clarity on the relationship between in 
vitro data and clinical outcomes for combination therapy, but outstanding questions, highlighted in 
recent reviews,7-11 include whether high-dose carbapenems might overcome lower-level resistance; 
whether old, potentially toxic drugs, such as colistin, are more effective in combination with other 
drugs; and whether alternative agents synergistically increase antimicrobial potency e.g. polymixin-
zidovudine12?  
 
Randomised controlled trials (RCT) provide the most robust evidence regarding the relative efficacy 
of different therapeutic options.13 However, despite the plethora of questions, there are few 
randomised trials in carbapenem-resistant infections. Clinical practice is currently guided by 
retrospective observational cohort studies, such as the INCREMENT study, where combination 
therapy was associated with improved clinical outcomes in higher risk patients.14 The challenges of 
undertaking RCTs are illustrated by the recent FDA-approved trial of plazomicin, which screened 
2000 adults to randomise only 39 over 2 years.15 Of note, the parallel trial of plazomicin versus 
meropenem for complicated urinary tract infection recruited 609 adults but had 0.2% mortality 
overall,16 making extrapolation to more serious infections challenging. One of the largest trials in 
carbapenem-resistant infections to date randomised 406 adults to colistin monotherapy vs 
colistin+meropenem.17 Whilst overall the trial found no evidence of benefit from 
colistin+meropenem, failure rates were numerically lower in the combination arm. A further 
challenge for comparative clinical efficacy studies is the future pipeline of antibiotics active against 
carbapenem-resistant infections.18 The great majority now in Phase 1 trials are active only against 
specific pathogens or resistance mutations, making broader comparisons of efficacy even more 
problematic.  
 
In a traditional 2-arm or multi-arm trial, eligible patients are randomised between control and all 
intervention regimens. First, there is no accepted optimal standard of care regimen that can be used 
as a control regimen for carbapenem-resistant infections. Second, any specific regimen may be 
contraindicated or unavailable for many patients with carbapenem-resistant infections for different 
reasons, greatly restricting eligibility and recruitment. For example, the antimicrobial susceptibility 
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of the infecting organism or the patient’s condition (e.g. renal impairment) may contraindicate 
either the control or intervention regimen. 
 
These factors make it hard to find any two specific regimens which most patients meeting other 
inclusion criteria could be randomised to, even though physicians may have many questions 
regarding an individual patient’s treatment. This makes conventional trial designs difficult, including 
“platform” designs, which maintain a control group over a longer period of time, against which 
different intervention regimens are compared, with the control potentially changing if a more 
effective regimen is identified.19,20  
 
What is the clinical question? 
Faced with a severely unwell patient with a life-threatening carbapenem-resistant infection (with a 
probable underlying mortality ≥10-20%), a clinician wishes to know, out of the X possible regimens 
(including combinations) that they could treat this patient with, which will provide the greatest 
probability of success (cure)? Given the high mortality associated with such infections, we argue that 
absolute confidence in identifying “the best” regimen is less important than avoiding the worst 
regimens. That is, choosing a regimen that is likely to be one of the best of the available options at 
that time for the individual patient is more important than choosing the perfectly optimal regimen. 
These are the clinical compromises that physicians make continuously: personalising decisions for 
each individual patient, balancing efficacy, toxicity, resistance, availability and cost.  
 
This scenario has an analogy in network meta-analysis,21 which compares multiple treatments in an 
evidence synthesis, to identify, overall, what is the best treatment out of a set of available 
treatments to recommend, and/or how do these different treatments rank against each other? The 
difference is that in network meta-analysis the unit is an RCT, directly comparing two or more 
regimens (potentially with different “control” comparators). The statistical challenge is ensuring that 
the individual pairwise within-trial comparisons are pooled together into a consistent coherent 
whole, taking into account uncertainty within each individual trial and between-trial variation. 
However, much theoretical work has gone into determining the best statistically principled methods 
to make indirect inferences about the relative performance of different regimens across the 
network,22,23 even when these may not have been directly compared within any one RCT. 
 
A new trial design 
We propose to exploit and extend the network meta-analysis approach to individual randomisation 
of patients in what we term a “Personalised RAndomised Controlled Trial” (PRACTical) design. Here 
we summarise its design principles; detailed statistical methodology will be reported elsewhere. 
 
There are multiple drugs or regimens that might be effective for carbapenem-resistant infections. 
Specifically, of a “network” of X regimens of interest, each patient would be randomised only to 
those regimens that were considered clinically reasonable for that patient at that time (i.e. reflecting 
individualised equipoise), incorporating antimicrobial susceptibility, toxicity profile, and physician 
judgement. We denote the subset of clinically acceptable regimens each patient’s “personalised 
randomisation list”. The set of patients with the same personalised randomisation list would then 
form the unit analogous to the trial in network meta-analysis. The full regimen list would be created 
by reviewing current literature, in discussion with industry if new drugs were included, and in 
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consultation with participating physicians across trial sites, as the proposed regimens must be widely 
acceptable and available. An example of how individual patients might be randomised in such a trial 
is shown in Table 1 with a flow diagram in Figure 1. 
 
We envisage the eligible population would be patients with bloodstream infections and 
hospital/ventilator associated pneumonia (HAP/VAP, as defined by FDA24/EMA25), highly likely or 
proven to be caused by a carbapenem-resistant organism (CRO) (CRE, Acinetobacter baumanii or 
Pseudomonas aeruginosa). These infections are still relatively uncommon in high-income settings 
but are now common in Asia,26 where such trials should be conducted. Patients would be 
randomised when the clinician decides to initiate therapy to treat a life-threatening proven or 
highly-likely carbapenem-resistant infection. Generally, this decision requires the results of culture 
and antimicrobial susceptibility testing, but may be influenced by known prior CRO colonisation or 
other epidemiological risk factors. 
 
The physician would consider the treatment options for each individual patient from the full regimen 
list based upon their assessment of the nature and antimicrobial susceptibility of the infecting 
organisms, clinical presentation, pharmacokinetic/pharmacodynamic properties of the drugs 
available, and the patient’s characteristics (Table 1). This could be conceptualised as a list of pre-
defined inclusion/exclusion criteria that the physician would use to determine the initial 
randomisation possibilities for each patient, which could then be further individualised into a 
“personal randomisation list” based on physician preference/local availability. Whilst there would 
likely be some clinician or site-specific preferences for certain regimens, given combination therapy 
choices in studies to date,26 this would likely vary markedly between sites, and even clinicians within 
sites. In practice, sufficient numbers of participating sites and prior assessment of site/physician 
preferences would ensure variation in the “personal randomisation lists” and overcome potential 
risks of restricted prescribing. A single protocol would harmonise delivery of each regimen and 
management. The number of different regimens and complexity of dosing would preclude blinding, 
but standard 2-arm trials in this area have been open-label for similar reasons. 
 
The trial endpoints should be objective (reducing the impact of lack of blinding) with direct relevance 
to patients and physicians. Both bloodstream infections and HAP/VAP are life-threatening infections. 
Therefore, we consider that Phase III trials, which aim to provide definitive, practice-changing, 
evidence, should have mortality as their primary endpoint.27 Syndrome-specific outcomes have been 
defined by regulators assessing licensing trials and these could also be included as endpoints.  
 
The primary analysis would be intention-to-treat, making a generalisability assumption that changes 
to antimicrobial therapy happening during the trial would represent those that happen outside the 
trial, and therefore the “as-randomised” comparison most closely reflects real-world effectiveness. 
However, one possibility would be to re-randomise such patients needing to change treatment for 
lack of response/deterioration or treatment-emergent toxicity to a new personalised list of 
acceptable regimens, exploiting the inverse probability weighting methods that underpin the 
Sequential Multiple Assignment, Randomized Trial (SMART) design28 to account for the subsequent 
randomisation. If cure was the primary efficacy endpoint, and change of regimen counted as a 
failure, then inverse probability weighting methods would not be required and patients could simply 
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be re-randomised, and this adjusted for in analysis.29 Changes from randomised treatment could also 
be adjusted for using inverse probability weighting methods.30 
 
Statistical considerations 
Extrapolating from network meta-analysis, initial simulations show that, of the various potential 
analysis methods, both a “network” analysis method and a “pairwise” analysis method give 
appropriate inference about differences between regimens. The network method corresponds to a 
common-effect network meta-analysis, combining direct and indirect evidence by assuming 
consistency (that relative treatment effects are the same for each patient type)23. Failure of 
consistency would be manifested by interactions as discussed in next paragraph. In the pairwise 
method, all data for each pairwise comparison of any two regimens (a “pair-wise” trial) are stacked 
and analysed using robust variance adjustments. Both methods ensure that direct comparisons 
between any pair of regimens are informed only by patients who are eligible for both regimens and 
are therefore comparable. Uncertainty will be expressed via confidence intervals around relative 
treatment effects, but our aim is not to demonstrate statistical significance and so there is no need 
to allow for multiple testing. In contrast, across a network the goal is essentially to “rank” the 
options and provide some degree of assurance that the top-ranked regimen that is relevant for any 
individual patient is one of the best regimens for that patient. That is, suppose a new patient can 
take regimens A, B, D, F, H and I from Table 1: the goal of a personalised randomised trial is to 
ensure that there is a high probability that the top-ranked regimen from this list based on the trial’s 
results provides an expected improvement in the primary outcome compared to any randomly 
chosen regimen from this list. 
 
One important challenge for all trials is variation in differences between regimens by, for example, 
heterogeneous types and severity of co-morbidity/underlying disease, i.e. subgroup effects or 
interactions, which even traditional trial designs are rarely powered to detect. However, the fact 
that our new design uses both indirect and direct evidence in any regimen comparison requires 
specific consideration and checking of consistency in the analysis. In all trials, not just this new 
proposed design, the main approach to dealing with heterogeneity in regimen comparisons is to 
restrict eligibility criteria to a more homogenous group and try to answer the questions within this 
group. The challenge is then generalising such results more broadly. The alternative is to enrol a 
broad and generalizable group of patients, and accept that power to detect all but the strongest 
interactions will be low. We favour the latter approach, since, given the underlying mechanism of 
action (bacterial killing), it is plausible that only qualitative (effect vs no effect) interactions are likely 
to be clinically important. The ranking analysis method above, however, could be applied within 
specific subgroups to investigate, for example, whether the top three regimen choices from any 
personalised randomisation list varied substantially across different patient subgroups. 
 
This raises the question as to whether such a trial should recruit adults/adolescents only, 
infants/children only or both, given the threat that CRO infections pose across the ages. Assuming 
appropriate dose adjustment for maturation, weight and kidney function (thus overcoming major 
age-driven differences in pharmacokinetics), the antimicrobial action of different drugs and 
combinations are unlikely to vary substantially by age. There is a recognised ethical obligation to 
ensure that children benefit from research to identify the best treatments for them the same as for 
adults.31 We can identify no current trials on CRO in children. A recent review of the global literature 
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noted a mortality of 36% from a total of 23 children and 38 neonates (Dona 2017). Therefore, we 
strongly advocate including all ages in the trial. A single independent Data Monitoring Committee 
would monitor safety and efficacy, e.g. using single-group Bayesian stopping rules to halt 
randomisation to regimens with unacceptable toxicity,32overall and by age group. 
 
Sample size 
Standard methods for determining sample size (e.g. in order to detect a clinically relevant 
improvement in outcome from “intervention” vs “comparator” regimen) do not apply to a network 
of regimens. Assuming 10 regimens in a network have overall 30-day mortality uniformly distributed 
between 10-30%, if hypothetically we could choose the true top-ranked regimen for each patient 
then we would reduce mortality by 5.5% on average across simulations compared to choosing a 
random regimen for each patient from the personalised randomisation list. This is therefore the 
maximum possible average reduction in mortality were perfect information on the true mortality 
under each regimen available. Randomising 1000 patients provides an expected mortality gain of 
4.6% from choosing the “top-ranked” regimen based on the trial’s results vs choosing a random 
regimen from the personalised randomisation list before the trial, i.e. gains 82% (4.6%/5.5%) of the 
maximum possible gain. It also provides a 90% probability that selecting the “top-ranked” regimen 
reduces an individual patient’s mortality risk vs choosing randomly. Mortality gains would be greater 
if some regimens have mortality much worse or better than 10-30%. One advantage of the regimen 
network is that, intrinsically to the design, most information is obtained about regimens which are 
acceptable to more patients, which will have proportionately greater numbers enrolled to them at 
the trial’s end. This maximises information available on these regimens and increases precision in 
their ranking, but without requiring patients to all have the potential to be randomised to a common 
control regimen.  
 
Implementation and impact 
The trial results would rank the regimens according to their efficacy, safety and cost (Figure 2). 
When faced with a new patient, their key characteristics and their infection (e.g. organism and its 
susceptibility profile, infection type, renal or liver function impairment) would determine which 
regimens are acceptable, and the ranking of these acceptable regimens on the primary outcome (30-
day mortality) would then suggest the obvious treatment choice in many situations (e.g. regimen A 
in Figure 2). Any major qualitative interactions could change the ranking for some key 
characteristics. However, the trial can also rank secondary outcomes, which may have different 
degrees of importance in different settings and for licensing trials. Similarly, if the two top-ranked 
regimens on mortality have very different toxicity profiles or ease of dosing, physicians may make 
different trade-offs depending on patient characteristics. These kinds of decisions could be 
facilitated by electronic clinical decision support systems for physicians, or formalised into 
institutional, national or eventually, WHO guidelines. 
 
Challenges 
Table 2 presents some advantages and disadvantages of the new design. There is no doubt that 
implementation would raise challenges, not least explaining the design to ethics committees in 
multiple sites across multiple countries. Interestingly, despite concerns about explaining more 
complex designs to patients and clinicians, multi-arm trials have generally recruited faster than 
standard 2-arm trials, possibly because they more closely reflect real-world uncertainties and hence 
8 
 
have greater salience.33 Regulatory approval for use of some drugs in a trial might be difficult, and 
could vary by country, but this might simply further restrict the personalised randomisation list for 
some patients. There will be competition for similar patients from innovator company CRO studies, 
which will provide high per-patient fees, but many patients are not eligible for such standard two-
arm licencing trials as noted above, but could enter the proposed personalised randomisation trial. 
Whether and how data from this novel design could support licensing applications would need 
discussion with FDA/EMA. Clinicians might potentially only wish to randomise between their top two 
choices for an individual patient, reducing power across the network of regimens: clear criteria for 
inclusion/exclusion of specific regimens and minimising the number of regimens that can be rejected 
for physician preference could mitigate this and increase generalisability. Recommending doses in 
patients likely to have at least moderate renal insufficiency (which may then improve on treatment) 
is challenging, particularly where access to therapeutic drug monitoring is limited and as most of the 




The major challenge to obtaining robust evidence on the most effective regimens for life-threatening 
carbapenem-resistant infections is that a large number of treatment options that are of interest in 
routine clinical care may not be relevant for any individual patient, preventing successful conduct of 
a traditional 2-arm or even multi-arm RCTs. The current, largely innovator company-led, single 
comparator trials are not designed to answer the urgent public health question, identified as a high 
priority by the WHO, of the best regimens out of the available options for an individual that will 
significantly reduce morbidity, costs, and mortality. We thus propose a novel trial design, building on 
network meta-analysis methods, to maximise the relevance to each individual patient, and enable 
the top-ranked regimens from any personalised randomisation list to be identified, in terms of both 




ASW, IRW and BT are supported by core support from the Medical Research Council UK to the MRC 
Clinical Trials Unit [MC_UU_12023/22, MC_UU_12023/29] through a concordat with the 
Department for International Development. ASW is also supported by the Oxford NIHR Biomedical 
Research Centre; and is an NIHR Senior Investigator. GT and NJW are supported by the Wellcome 
Trust, UK. The views expressed are those of the author(s) and not necessarily those of the NHS, the 
NIHR, the Department of Health or PHE.  
 
Contributions  
The concept was developed by ASW, IRW, BT, MS and GT, with input from all other authors. The 
manuscript was drafted by ASW, IRW, MS and GT with review and comment from all authors. 
 
Conflict of Interest 
MS is Chair of the Antibiotic Working Group of the WHO Expert Committee on the Selection and Use 






1. Bush K. Past and Present Perspectives on beta-Lactamases. Antimicrob Agents Chemother 
2018; 62(10). 
2. Drusano GL, Neely MN, Yamada WM, et al. The Combination of Fosfomycin plus Meropenem 
Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model. Antimicrob 
Agents Chemother 2018; 62(12). 
3. Pryjma M, Burian J, Kuchinski K, Thompson CJ. Antagonism between Front-Line Antibiotics 
Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections Is Mediated 
by the whiB7 Gene. Antimicrob Agents Chemother 2017; 61(11). 
4. McAleenan A, Ambrose PG, Bhavnani SM, et al. Methodological features of clinical 
pharmacokinetic-pharmacodynamic studies of antibacterials and antifungals: a systematic review. J 
Antimicrob Chemother 2020. 
5. Bulitta JB, Hope WW, Eakin AE, et al. Generating Robust and Informative Nonclinical In Vitro 
and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans. Antimicrob 
Agents Chemother 2019; 63(5). 
6. Rizk ML, Bhavnani SM, Drusano G, et al. Considerations for Dose Selection and Clinical 
Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents. Antimicrob 
Agents Chemother 2019; 63(5). 
7. Carrara E, Bragantini D, Tacconelli E. Combination versus monotherapy for the treatment of 
infections due to carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis 2018; 31(6): 594-9. 
8. Sheu CC, Chang YT, Lin SY, Chen YH, Hsueh PR. Infections Caused by Carbapenem-Resistant 
Enterobacteriaceae: An Update on Therapeutic Options. Front Microbiol 2019; 10: 80. 
9. Piperaki ET, Tzouvelekis LS, Miriagou V, Daikos GL. Carbapenem-resistant Acinetobacter 
baumannii: in pursuit of an effective treatment. Clin Microbiol Infect 2019; 25(8): 951-7. 
10. Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem-resistant 
Enterobacteriaceae infections. Clin Microbiol Infect 2019; 25(8): 943-50. 
11. Gutierrez-Gutierrez B, Rodriguez-Bano J. Current options for the treatment of infections due 
to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients. 
Clin Microbiol Infect 2019; 25(8): 932-42. 
12. Lin YW, Abdul Rahim N, Zhao J, et al. Novel Polymyxin Combination with the Antiretroviral 
Zidovudine Exerts Synergistic Killing against NDM-Producing Multidrug-Resistant Klebsiella 
pneumoniae. Antimicrob Agents Chemother 2019; 63(4). 
13. Barton S. Which clinical studies provide the best evidence? The best RCT still trumps the best 
observational study. BMJ 2000; 321(7256): 255-6. 
14. Gutierrez-Gutierrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination 
therapy on mortality of patients with bloodstream infections due to carbapenemase-producing 
Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis 2017; 17(7): 726-
34. 
15. McKinnell JA, Dwyer JP, Talbot GH, et al. Plazomicin for Infections Caused by Carbapenem-
Resistant Enterobacteriaceae. N Engl J Med 2019; 380(8): 791-3. 
16. Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-Daily Plazomicin for Complicated 
Urinary Tract Infections. N Engl J Med 2019; 380(8): 729-40. 
17. Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem 
for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an 
open-label, randomised controlled trial. Lancet Infect Dis 2018; 18(4): 391-400. 
18. World Health Organization. Antibacterial agents in clinical development: An analysis of the 
antibacterial clinical development pipeline, including tuberculosis. Geneva, Switzerland: World 
Health Organization, 2017. 
10 
 
19. Parmar MK, Sydes MR, Cafferty FH, et al. Testing many treatments within a single protocol 
over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and 
basket protocols. Clin Trials 2017; 14(5): 451-61. 
20. Lanini S, Ioannidis JPA, Vairo F, et al. Non-inferiority versus superiority trial design for new 
antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive 
randomised controlled trials. Lancet Infect Dis 2019. 
21. Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern 
Emerg Med 2017; 12(1): 103-11. 
22. Riley RD, Jackson D, Salanti G, et al. Multivariate and network meta-analysis of multiple 
outcomes and multiple treatments: rationale, concepts, and examples. BMJ 2017; 358: j3932. 
23. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat 
Methods Med Res 2008; 17(3): 279-301. 
24. US Department of Health and Human Services UFaDA, Center for Drug Evaluation and 
Research (CDER), . Guidance for industry. Hospital-acquired bacterial pneumonia and ventilator-
associated bacterial pneumonia: developing drugs for treatment 
(https://www.fda.gov/downloads/drugs/guidances/ucm234907.pdf). , 2014. 
25. European Medicines Agency. Addendum to the guideline on the evaluation of medicinal 
products indicated for treatment of bacterial infections 
(https://www.ema.europa.eu/en/documents/scientific-guideline/addendum-guideline-evaluation-
medicinal-products-indicated-treatment-bacterial-infections_en.pdf). 2013. 
26. Stewardson AJ, Marimuthu K, Sengupta S, et al. Effect of carbapenem resistance on 
outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income 
countries (PANORAMA): a multinational prospective cohort study. Lancet Infect Dis 2019; 19(6): 601-
10. 
27. Harris PNA, McNamara JF, Lye DC, et al. Proposed primary endpoints for use in clinical trials 
that compare treatment options for bloodstream infection in adults: a consensus definition. Clin 
Microbiol Infect 2017; 23(8): 533-41. 
28. Almirall D, Nahum-Shani I, Sherwood NE, Murphy SA. Introduction to SMART designs for the 
development of adaptive interventions: with application to weight loss research. Transl Behav Med 
2014; 4(3): 260-74. 
29. Kahan BC, Forbes AB, Dore CJ, Morris TP. A re-randomisation design for clinical trials. BMC 
Med Res Methodol 2015; 15: 96. 
30. Hernan MA, Robins JM. Per-Protocol Analyses of Pragmatic Trials. N Engl J Med 2017; 
377(14): 1391-8. 
31. Burman WJ, Cotton MF, Gibb DM, Walker AS, Vernon AA, Donald PR. Ensuring the 
involvement of children in the evaluation of new tuberculosis treatment regimens. PLoS Med 2008; 
5(8): e176. 
32. Zohar S, Teramukai S, Zhou Y. Bayesian design and conduct of phase II single-arm clinical 
trials with binary outcomes: a tutorial. Contemp Clin Trials 2008; 29(4): 608-16. 
33. Parmar MK, Carpenter J, Sydes MR. More multiarm randomised trials of superiority are 





Table 1 Example of a personalised randomised trial design  
Possible regimens 




























A: plazomicin No/maybe†     No No  
B: ceftazidime/avibactam No/maybe†     No  No 
C: cefiderocol maybe†       No 
D: high-dose meropenem* maybe†  No      
E: polymixin B±zidovudine  No/maybe†    No     
F: high-dose meropenem*+ertapenem maybe†  No  No    
G: high-dose meropenem*+imipenem No/maybe†  No      
H: high-dose meropenem*+polymixin 
B±zidovudine 
No/maybe†  No No     
I: high-dose meropenem*+high-dose 
tigecyline 
maybe† No No  No    
J: high-dose meropenem*+fosfomycin maybe†  No      
K: high-dose tigecyline+polymixin 
B±zidovudine 
No/maybe† No  No No    
L: high-dose tigecyline+fosfomycin maybe† No   No    
M: fosfomycin+polymixin B±zidovudine No/maybe†   No     
Physician decides patient can be 
randomised to: 
C D F I J L A B C D  
E F G H J M 
A B C K M A B C D F 
G I J L 
A B C D E  
G H J M 
All except A 
and B 
All except A All except B 
and C 
* using continuous or prolonged infusion (over at least 3h). 
† dose adjustments required in patients with renal impairment which may or may not be judged feasible in an individual patient. 
** based on plausibility as assessed by high MIC 
Note: MIC=median inhibitory concentration, VAP/HAP=ventilator acquired pneumonia/hospital-acquired pneumonia. High-dose meropenem 2g every 8h. 
High-dose tigecycline 200mg loading dose and a maintenance dose of 100mg every 12h.  
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Table 2. Advantages and disadvantages of personalised randomised controlled trial designs 
Advantages Disadvantages 
No requirement for pre-defined standard of care 
control group, facilitating wide recruitment 
across ages, centres and countries. 
Complex statistical methods supporting the 
design (no hypothesis testing), potentially 
reducing wider understanding and future buy-in 
No requirement that both control and all 
intervention(s) groups can be taken by all 
randomised patients, enhancing recruitment 
Standard sample size calculations cannot be 
used  
Pre-trial engagement with physicians in 
construction of full randomisation list increasing 
trial buy-in and subsequent recruitment 
Novel concept of ranking regimens according to 
efficacy and safety: direct clinical utility may take 
time 
Pragmatic eligibility criteria enhancing 
recruitment 
Likely to require multiple participating sites and 
physicians to overcome risk of limited 
prescribing and restricted use of the full 
randomisation list 
Provides outcomes that can inform individual 
countries public health decisions  
Design may be perceived as “too complicated” 
Faster recruitment and multiple randomised 
groups gives quicker results on more relevant 
regimens 
Ethical committees may not understand or easily 
approve the design 
Personalised randomisation list enhances 
potential benefit to patient from joining the trial, 
by enabling the regimens they can be 
randomised to be more individually relevant 
Will require substantial discussions with 
regulators to become applicable to licensing 
trials 
Trial mirrors normal clinical practice, easing on-
the-ground delivery 
 
Trial produces an easy to understand ranking of 
multiple patient and physician focused outcomes 
 
Results may lead to electronic clinical decision 
support systems that provide better targeted 







Figure 1 Flow diagram of participants through the trial 
 
Figure 2 Hypothetical ranking of regimens from a personalised randomisation list (A B D F H I, from 
table 1) for a future individual patient after the trial 
 
 
